Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 4/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14824670 | 0.81 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1TYRO3DYRK1BPIN1 | |
| SCHEMBL3139494 | 0.81 | ALDH1A1 (0.44) | XDHYTHDC1PDE2AALDH1A1L3MBTL1 | |
| SCHEMBL23142088 | 0.80 | TDP1 (0.37) | ALDH1A1L3MBTL1TYRO3DYRK1BPIN1 | |
| SCHEMBL14809903 | 0.80 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1KMT2ASTK17BSTK17A | |
| SCHEMBL15624861 | 0.78 | MEN1 (0.31) | ALDH1A1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14038741 | 0.78 | — | — | |
| SCHEMBL5677080 | 0.78 | JUN (0.42) | ALDH1A1L3MBTL1TYRO3DYRK1BPOLB | |
| SCHEMBL22866258 | 0.78 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1POLBKMT2ASTK17B | |
| SCHEMBL5763052 | 0.77 | NUDT1 (0.38) | L3MBTL1 | |
| SCHEMBL5789412 | 0.76 | NUDT1 (0.42) | ALDH1A1L3MBTL1KMT2AJAK2STK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014138485-A1 | EX VIVO PRODUCTION OF PLATELETS FROM HEMATOPOIETIC STEM CELLS AND THE PRODUCT THEREOF | IRM LLC (BM) | 2014-09-12 | — | — | WO | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2010-09-16 | — | — | US | disclosed |
| US-7642255-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2010-01-05 | — | — | US | disclosed |
| EP-1651648-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-02 | — | — | EP | disclosed |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| CN-101238129-A | Compounds that maintain pluripotency of embryonic stem cells | IRM LLC (BM) | 2008-08-06 | — | — | CN | disclosed |
| US-7371750-B2 | Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs | IRM LLC (BM) | 2008-05-13 | — | — | US | disclosed |
| EP-1899344-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM, LLC (BM) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135824-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | IRM LLC (BM) | 2006-12-21 | — | — | WO | disclosed |
| CN-1860118-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2006-11-08 | — | — | CN | disclosed |
| EP-1651648-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-10-06 | — | — | US | disclosed |
| WO-2005011597-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234400-A1 | COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS | LIFR, ALPG, BMI1 | XDH 1573/4885YTHDC1 4208/4885PDE2A 2929/4885 |
| US-20050222177-A1 | Compounds and compositions as protein kinase inhibitors | BMX, FES, FRK | XDH 3691/4885YTHDC1 4774/4885PDE2A 3026/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | XDH 3564/4885YTHDC1 2789/4885PDE2A 710/4885 |
| US-20080221098-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BMX, FES, FRK | XDH 3691/4885YTHDC1 4774/4885PDE2A 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.